Current landscape of mRNA therapeutics for acute myeloid leukemia
Experimental Hematology · 2026-06 · 158 · 105406
DOI: 10.1016/j.exphem.2026.105406 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Experimental Hematology, 2026-06. Verfasst von Mira Hamed und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Therapeutics, McGill University, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, RNA, Messenger, Genetic Therapy. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canada Research Chairs Program, OpenAI, Canadian Cancer Society.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology & Therapeutics, McGill University, Montreal, Quebec, Canada.
- Department of Pharmacology & Therapeutics, McGill University, Montreal, Quebec, Canada; Department of Chemistry, McGill University, Montreal, Quebec, Canada. Electronic address: maureen.mckeague@mcgill.ca.
Förderung
- Canada Research Chairs Program
- OpenAI
- Canadian Cancer Society
- Canadian Institutes of Health Research
Zitieren
APA
Hamed, M., Kovecses, O., & McKeague, M. (2026). Current landscape of mRNA therapeutics for acute myeloid leukemia. Experimental Hematology, 158, 105406. https://doi.org/10.1016/j.exphem.2026.105406
Vancouver
Hamed M, Kovecses O, McKeague M. Current landscape of mRNA therapeutics for acute myeloid leukemia. Experimental Hematology. 2026;158:105406. doi:10.1016/j.exphem.2026.105406
BibTeX
@article{Hamed2026,
author = {Hamed, Mira and Kovecses, Olivia and McKeague, Maureen},
title = {Current landscape of mRNA therapeutics for acute myeloid leukemia},
journal = {Experimental Hematology},
year = {2026},
volume = {158},
pages = {105406},
doi = {10.1016/j.exphem.2026.105406}
}
EUVIMED